| Date | Title | Description |
| 26.09.2024 | AstraZeneca in AI collaboration with Immunai to inform cancer drug trials | AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more efficient, the latter said on Thursday.
This is the latest in a string... |
| 18.06.2022 | How AI and human intelligence will beat cancer | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
2016 saw the completion of a significant mileston... |
| 20.01.2022 | More And More Israelis Are Growing Horns: Startup Nation Out, Big Tech Nation In | This might sound strange, but Israelis are growing horns more than ever before;unicorn horns, that is (why, what did you think I was talking about?). World, pay attention: more than 35 companies in Israel reached unicorn status over the las... |
| 04.01.2022 | The convergence of deep neural networks and immunotherapy | Luis Voloch Contributor
Share on Twitter
Luis Voloch is the CTO and co-founder of Immunai. He was previously Israel Tech Challenge’s head of data science, worked on varied machine learning efforts at Palantir and led the machine learning in... |
| 29.11.2021 | ML-driven tech is the next breakthrough for advances in biology | Hear from CIOs, CTOs, and other C-level and senior execs on data and AI strategies at the Future of Work Summit this January 12, 2022. Learn more
This article was contributed by Luis Voloch, cofounder and chief technology officer at Immunai... |
| 29.11.2021 | ML-driven tech is the next breakthrough for advances in biology | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
This article was contributed by Luis Voloch, cofo... |
| 30.10.2021 | US-based Biotech startup Immunai raises USD 125 million in Series B round | Immunai, a New York-based biotech startup, has raised USD 125 million in a Series B funding round led by Koch Disruptive Technologies on 27 October 2021. |
| 29.10.2021 | The lines between VCs and other investors are getting blurry | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Happy Friday, Term Sheet readers. Finance reporter Anne Sraders here, filling in for Lucinda (she... |
| 29.10.2021 | Immunai raises USD 215 million for its drug discovery platform | Israeli-founded biotech startup Immunai announced this week that it has raised a USD 215 million Series B round for its drug discovery platform, led by Koch Disruptive Technologies, with participation from Talos VC, 8VC, Alexandria Venture ... |
| 27.10.2021 | Immunai announces a $215M Series B as its ‘immune cell atlas’ matures | Biotech startup Immunai has been on a roll when it comes to funding. The company that set out to create an atlas of the human immune system in 2018 had raised about $80 million by February 2021. On Wednesday, the company announced another s... |
| 27.10.2021 | Daily funding roundup - October 27, 2021 | Truepill raised $142M; Cornami landed $50M; Extend secured $40M; Shiru picks up a $17M
Clickup: Clickup is a San Diego, Ca.-based workplace productivity platform. Clickup has raised $400 million in Series C funding co-led by Andreessen Horo... |
| 27.10.2021 | Immunai Raises $215 Million in Series B Funding | Immunai, a New York-based biotech company, raised $215M in Series B funding, increasing the company’s total funding to date to $295M.
The Series B was led by Koch Disruptive Technologies, with participation from Talos VC, 8VC, Alexandria Ve... |
| 16.08.2021 | 15 Budding Industries For Biz Dev Newcomers To Explore | Every small change in the business development industry brings career opportunities for professionals newly entering the field. With technological advancements expanding the boundary of what it means to help customers and changing how that ... |
| 02.08.2021 | Nebion becomes a subsidiary of New-York based Immunai | Founded in 2010, Nebion specialises in curating public gene expression datasets and developing intuitive discovery tools. Its data mining engine is deeply curated with the highest quality transcriptomic data of microarrays and RNA-sequence,... |
| 11.02.2021 | Immunai Raises $60M in Series A Funding | Immunai, a New York based biotech company, raised $60M in Series A funding, increasing total funding-to-date to over $80M.
The Series A round was led by Schusterman Family Investments, Duquesne Family Office, Catalio Capital Management, and... |
| 11.02.2021 | Immunai raises $60M as it expands from improving immune therapies to discovering new ones, too | Just three years after its founding, biotech startup Immunai has raised $60 million in Series A funding, bringing its total raised to over $80 million. Despite its youth, Immunai has already established the largest database in the world for... |
| 11.02.2021 | Immunai raises $60 million to analyze the immune system with AI | Immunai, a startup developing an AI platform to analyze the human immune system, today announced that it raised $60 million. The company says it will use the funds to broaden its functional genomics capabilities and help its partners priori... |
| 11.02.2021 | Immunai raises $60M with the goal of reprogramming the human immune system | The company uses single-cell tech and AI to discover and develop new therapies and drug combinations
Last year, Immunai, a New York and Tel Aviv-based biotech company, launched with the ambitious goal of mapping the human immune system, usi... |
| 11.02.2021 | Immunai raises $60 million to analyze the immune system with AI | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
Immunai, a startup developing an AI platform to a... |
| 15.05.2020 | Immunai launches with $20M to map the human immune system | The company has already mapped out millions of immune cells and their functions
It hasn't been all that long since we unlocked the human genome, but the effect on healthcare has already been massive. It's even led to a whole new category, p... |
| 15.05.2020 | Predicting immune system with AI: US-Israeli biotech startup Immunai scores €18.5M funding | Immunai is a biotech company that’s on a mission to fully map the immune system to better detect, diagnose, and treat disease by advancing personalised medicine through a comprehensive understanding of the immune system. Raised €18.5 millio... |
| 14.05.2020 | Immunai Launches With $20M Seed Funding And Plan To Map The Immune System | 33 Shares Email Facebook Twitter LinkedIn
Immunai came out of stealth mode Thursday with two things: a mission to map the entire immune system and its functions using machine learning, and a capital infusion of $20 million in seed funding.
... |
| 14.05.2020 | Immunai wants to map the entire immune system and raised $20 million in seed funding to do it | For the past two years the founding team of Immunai had been working stealthily to develop a new technology to map the immune system of any patient.
Founded by Noam Solomon, a Harvard and MIT-educated postdoctoral researcher, and former Pal... |
| 14.05.2020 | Immunai decloaks with $20M in seed funding to map immune system with machine learning | “When looking at only a specific disease or patient cohort, one gets a limited and siloed view of the immune system,” Solomon said in a statement. “By using machine learning and applying it to our proprietary diverse database of single-sequ... |
| 14.05.2020 | Immunai raises $20 million for AI that predicts immune response | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
Immunai, a startup developing a proprietary corpu... |
| 14.05.2020 | Immunai Raises $20M in Seed Funding | Immunai, a New York-based company which has launched out of stealth to map the entire immune system for detection, diagnosis, and treatment of disease, raised $20M in seed funding.
The round was led by Viola Ventures and TLV Partners.
The c... |
| 14.05.2020 | Immunai Launches With $20M Seed Funding And Plan To Map The Immune System | 32 Shares Email Facebook Twitter LinkedIn
Immunai came out of stealth mode Thursday with two things: a mission to map the entire immune system and its functions using machine learning, and a capital infusion of $20 million in seed funding.
... |
| 14.05.2020 | U.S.-Israeli biotech startup Immunai raises $20 million | TEL AVIV (Reuters) - U.S.-Israeli startup Immunai, which has mapped the immune system to help detect and treat disease, said on Thursday it has raised $20 million in seed funding led by Viola Ventures and TLV Partners.
The funds will be use... |
| - | Immunai decloaks with $20M in seed funding to map immune system with machine learning | A company developing means to use machine learning to map the immune system and thus aid the development of cell therapies and cancer immunotherapies is emerging from stealth mode with a hefty round of seed funding.
New York-based Immunai s... |
| - | Immunai Raises $20M to Provide a Complete Understanding of the Immune System With Single Cell Profiling | 501SHARES
FacebookTwitter
Linkedin
The human immune system is one of the most complex systems and still remains a mystery to scientists and researchers, partly due to the trillions of cells making it up. Many companies are trying to decode ... |
| - | Immunai Raises $60M to Decode the Immune System with Machine Learning and AI | 407SHARES
FacebookTwitter
Linkedin
The immune system at its core is a complex system of cells, organs, and tissues. These components work in unison to fight infection in the form of microbes. Developing an understanding of how this intricat... |
| - | Israeli biotech startup Immunai raises $215m for drug discovery platform | Israeli startup Immunai raised $215 million in a Series B funding round led by Koch Disruptive Technologies, the venture capital firm of Koch Industries, the company announced late Wednesday.
Immunai, founded in 2019, says it is on a missio... |